Volitionrx Ltd (VNRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Volitionrx Ltd (VNRX) has a cash flow conversion efficiency ratio of 0.154x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.49 Million) by net assets ($-35.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Volitionrx Ltd market capitalisation for the company's overall valuation and market capitalisation.
Volitionrx Ltd - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Volitionrx Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Volitionrx Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Volitionrx Ltd ranked by their cash flow conversion efficiency. Explore VNRX cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Southern Fertilizer JSC
VN:SFG
|
0.325x |
|
Foresta Group Holdings Ltd
AU:FGH
|
-0.582x |
|
SIMPPLE LTD. Ordinary Shares
NASDAQ:SPPL
|
0.712x |
|
Sensen Networks Ltd
AU:SNS
|
0.144x |
|
Seker Finansal Kiralama AS
IS:SEKFK
|
0.184x |
|
Salee Colour Public Company Limited
BK:COLOR
|
0.066x |
|
Microlink Solutions Bhd
KLSE:0126
|
-0.327x |
|
Pelikan International Corp
KLSE:5231
|
-0.039x |
Annual Cash Flow Conversion Efficiency for Volitionrx Ltd (2004–2025)
The table below shows the annual cash flow conversion efficiency of Volitionrx Ltd from 2004 to 2025. View latest Volitionrx Ltd stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-35.59 Million | $-19.68 Million | 0.553x | -44.24% |
| 2024-12-31 | $-26.11 Million | $-25.89 Million | 0.992x | -52.16% |
| 2023-12-31 | $-8.71 Million | $-18.06 Million | 2.073x | -57.56% |
| 2022-12-31 | $-3.13 Million | $-15.28 Million | 4.886x | +515.21% |
| 2021-12-31 | $17.72 Million | $-20.85 Million | -1.177x | -16.45% |
| 2020-12-31 | $16.29 Million | $-16.46 Million | -1.010x | -12.62% |
| 2019-12-31 | $14.20 Million | $-12.74 Million | -0.897x | +26.07% |
| 2018-12-31 | $12.14 Million | $-14.73 Million | -1.214x | +0.89% |
| 2017-12-31 | $9.96 Million | $-12.19 Million | -1.224x | -186.32% |
| 2016-12-31 | $21.18 Million | $-9.06 Million | -0.428x | +70.51% |
| 2015-12-31 | $6.04 Million | $-8.77 Million | -1.450x | +87.10% |
| 2014-12-31 | $368.18K | $-4.14 Million | -11.247x | -148.21% |
| 2013-12-31 | $680.67K | $-3.08 Million | -4.531x | -63.23% |
| 2012-12-31 | $833.79K | $-2.31 Million | -2.776x | -79.29% |
| 2011-12-31 | $1.09 Million | $-1.69 Million | -1.548x | -3905.47% |
| 2010-12-31 | $-114.29K | $-4.65K | 0.041x | -23.90% |
| 2009-12-31 | $-107.54K | $-5.75K | 0.053x | +112.84% |
| 2008-12-31 | $-95.92K | $39.95K | -0.416x | -288.41% |
| 2007-12-31 | $-78.32K | $-17.31K | 0.221x | -75.14% |
| 2006-12-31 | $-56.23K | $-50.00K | 0.889x | +185417.27% |
| 2005-12-31 | $-72.94K | $35.00 | 0.000x | -148.77% |
| 2004-12-31 | $-64.03K | $-63.00 | 0.001x | -- |
About Volitionrx Ltd
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleos… Read more